BioSpace News Archive

Magellan Health, Inc. announced that Jonathan N. Rubin, chief financial officer of Magellan Health, will participate in a fireside chat at the Stephens Nashville Investment Conference on Friday, November 15, 2019, at the Omni Nashville Hotel in Nashville, Tenn.

Palleon Pharmaceuticals, a leading biotech company developing drugs that target the Siglec-Sialoglycan axis to treat cancer, announced two poster presentations at the Society for Immunotherapy of Cancer’s 34th Annual Meeting in National Harbor, MD.

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corp for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.

Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle Drug Delivery Technology, reported financial results for the third quarter ended September 30, 2019.

BioXcel Therapeutics, Inc. announced it will host a conference call and webcast on Thursday, November 14, 2019 at 8:30 AM Eastern Time to discuss its third quarter 2019 operating and financial results.

TransThera Biosciences Co. Ltd, announced that company received Orphan Drug Designation from US Food and Drug Administration for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma.

At the Extra General Meeting held in Biotage AB (Reg. No. 556539-3138) on November 7, 2019, the following resolutions were passed, among others.

A new survey from Health Union, Atopic Dermatitis In America 2019, finds that people who begin experiencing atopic dermatitis symptoms as children have vastly different patient journeys and experiences, from those who began experiencing symptoms as adults.

Nurx, the health tech company providing convenient and affordable care for sensitive health needs, is now available in Maine.

BioMatrix Specialty Pharmacy announced Meagan Sampogna, PhD, RHIA has joined the organization as the company’s Chief Operations Officer.